• Poly (I:C): Synthetic dsRNA Analog for Advanced Immune Ac...

  2025-10-04

  Poly (I:C) empowers cutting-edge research by simulating viral infection, driving potent innate immune responses, and enabling precise dendritic cell maturation. Its robust TLR3 agonism and versatility make it indispensable for workflows in antiviral, cancer immunotherapy, and stem cell-derived cardiomyocyte studies.

• Canagliflozin Hemihydrate: Beyond SGLT2 Inhibition in Glu...

  2025-10-03

  Explore the multifaceted role of Canagliflozin hemihydrate as a small molecule SGLT2 inhibitor for advanced glucose metabolism and diabetes mellitus research. This article uniquely delves into the compound’s selectivity, biochemical properties, and specificity—addressing off-target questions, assay design, and its value in translational metabolic disorder research.

• Gefitinib (ZD1839): Selective EGFR Inhibitor in Advanced ...

  2025-10-02

  Gefitinib (ZD1839) transforms translational oncology by enabling selective EGFR inhibition in complex, patient-derived tumor models. Its application in assembloid systems advances personalized therapy discovery and exposes microenvironment-driven drug resistance. Harness its power for reproducible, data-rich preclinical results.

• Berbamine Hydrochloride: An Advanced NF-κB Inhibitor for ...

  2025-10-01

  Berbamine hydrochloride stands out as a next-generation anticancer drug and NF-κB inhibitor, delivering robust cytotoxicity in both leukemia and hepatocellular carcinoma models. Its high solubility and selectivity empower researchers to explore novel ferroptosis-sensitization strategies and dissect NF-κB signaling with precision.

• Mitomycin C in Translational Oncology: Mechanistic Insigh...

  2025-09-30

  This thought-leadership article explores Mitomycin C as a mechanistically unique antitumor antibiotic and DNA synthesis inhibitor, illuminating its role in apoptosis signaling and chemotherapeutic sensitization. Bridging foundational cell death biology with actionable strategies for translational researchers, we contextualize Mitomycin C’s capacity to potentiate TRAIL-induced and p53-independent apoptosis, drawing on liver disease cell death paradigms and current oncology models. By critically engaging with recent literature and advancing beyond conventional product narratives, this article offers a visionary blueprint for integrating Mitomycin C into the next generation of cancer research.

• Metronidazole as a Precision Tool: New Frontiers in OAT3 ...

  2025-09-29

  Explore the distinct role of Metronidazole as a nitroimidazole antibiotic and OAT3 inhibitor, with a focus on its emerging applications in Th1/Th2 immune modulation and drug-drug interaction research. This article provides advanced scientific insights and fills critical knowledge gaps not covered in prior reviews.

• DMH1 as a Precision Tool for Dynamic BMP Signaling Contro...

  2025-09-28

  Explore how DMH1, a selective BMP type I receptor inhibitor, enables unprecedented precision in modulating BMP signaling for advanced organoid engineering and non-small cell lung cancer research. This article uniquely examines dynamic, tunable pathway control and translational applications of DMH1 beyond current literature.

• (S)-Mephenytoin in Translational Drug Metabolism: Beyond ...

  2025-09-27

  (S)-Mephenytoin, a gold-standard CYP2C19 substrate, is transforming translational research in oxidative drug metabolism and pharmacokinetics. This article uniquely explores its integration with hiPSC-derived intestinal organoids and addresses emerging challenges in modeling inter-individual variability, surpassing routine in vitro assays.

• Redefining CRISPR Precision: EZ Cap™ Cas9 mRNA (m1Ψ) in M...

  2025-09-26

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) elevates genome editing in mammalian cells through advanced mRNA engineering, Cap1 structure, and N1-Methylpseudo-UTP modification. This in-depth analysis highlights a new paradigm for specificity and safety in CRISPR-Cas9 genome editing.

• Y-27632 Dihydrochloride: Advanced ROCK Inhibition for Int...

  2025-09-25

  Explore the multifaceted role of Y-27632 dihydrochloride as a selective ROCK1/ROCK2 inhibitor in engineering the intestinal stem cell niche, with insights into cytoskeletal modulation, regenerative medicine, and the latest advances in ISC aging research. This article provides a unique, in-depth perspective on Rho/ROCK signaling pathway manipulation for next-generation stem cell and cancer studies.

• Unveiling HyperScribe™ T7: Transforming RNA Synthesis for...

  2025-09-24

  Discover how the HyperScribe T7 High Yield RNA Synthesis Kit advances in vitro transcription RNA kit technology for high-yield, functional RNA generation. This article uniquely explores its pivotal role in functional genomics and metastatic cancer research.

• Rucaparib (AG-014699): Illuminating PARP1 Inhibition and ...

  2025-09-23

  Explore the scientific advances of Rucaparib (AG-014699) as a potent PARP1 inhibitor in DNA damage response research, with a novel focus on its intersection with regulated cell death pathways. This article provides new insights for cancer biology research, particularly in PTEN-deficient and ETS gene fusion-expressing prostate cancer models.

• In this study we have isolated genes

  2025-04-19

  

  In this study, we have isolated Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) that encode ACL from G. zeae through random mutagenesis by restriction enzyme-mediated integration (REMI). The mutant Z39P186 where the ACL gene had been disrupted showed defects in vegetative growth, as

• While it is known that circulating LDL C

  2025-04-18

  

  While it is known that circulating LDL-C levels are largely regulated by either controlling the rate of hepatic production of its triglyceride-rich precursor VLDL particle or the rate of LDLR-mediated LDL particle clearance [58], it should be noted that important differences exist between rodents an

• Consistent with a damaging role for increased LOX activity

  2025-04-18

  

  Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he

15751 records 1/1051 page Next 12345 下5页 Last page